一種微創(chuàng)分子血液檢查方法能夠幫助醫(yī)生檢查和診斷肺癌。這項檢查獲得了CE標(biāo)記，將使用CellCorrect KvA-40實驗室試劑盒的商標(biāo)在歐洲上市。

根據(jù)CeMines公司(Golden, CO, USA)的說法，這種新型檢測方法并不十分昂貴，能夠檢測血液中自身免疫的病變和與疾病相關(guān)的抗體，這些抗體主要是免疫系統(tǒng)產(chǎn)生的。CeMines稱這種技術(shù)為分子指紋圖譜。

該公司已經(jīng)開展全球患者的臨床研究，以證實特異性指標(biāo)的一致性，這些指標(biāo)已經(jīng)被證實能夠反應(yīng)癌癥的分化和特征。CeMines使用正在申請的分析復(fù)雜生物資料的應(yīng)用軟件用于生物指標(biāo)的分析，并使用特異性模式識別運算法則。這些資料十分便于閱讀評分，不需要醫(yī)生的主觀解釋。

Blood Test for Lung Cancer
 
A new minimally invasive molecular blood test is designed to help doctors detect and diagnose lung cancer. The test has received the CE Mark and will be marketed in Europe under the brand name CellCorrect KvA-40 lab kit.

The new test is an inexpensive way to detect altered autoimmunity and associated patterns of disease-related autoantibodies in the bloodstream that are produced by the immune system, according to the test’s developer, CeMines, Inc. (Golden, CO, USA). CeMines calls its technology Molecular FingerPrinting.

The company has conducted international patient studies that demonstrated consistent patterns of specific biomarkers that have proven their utility as viable composite biomarkers able to differentiate and characterize cancer. CeMines uses a patent-pending bioinformatics application for biomarker analysis, followed by specific pattern-recognition algorithms. The data are presented in an easy-to-read score that does not require subjective interpretation by doctors.